Certara, Inc. (NASDAQ:CERT) Receives $15.92 Average Target Price from Analysts

Certara, Inc. (NASDAQ:CERT) has earned an average rating of “Hold” from the eight analysts that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.92.

Several equities analysts have weighed in on CERT shares. Barclays cut their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Finally, Robert W. Baird decreased their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th.

Certara Price Performance

Shares of NASDAQ CERT opened at $10.71 on Monday. Certara has a 52-week low of $9.99 and a 52-week high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business has a fifty day moving average of $10.97 and a two-hundred day moving average of $13.58.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period last year, the firm posted $0.06 EPS. As a group, research analysts forecast that Certara will post 0.27 EPS for the current year.

Insider Activity

In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Institutional Trading of Certara

Institutional investors have recently made changes to their positions in the business. Blue Trust Inc. bought a new position in Certara in the second quarter valued at $26,000. Innealta Capital LLC bought a new position in shares of Certara in the 2nd quarter valued at about $36,000. KBC Group NV increased its position in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares during the last quarter. Intech Investment Management LLC bought a new stake in Certara during the second quarter worth about $152,000. Finally, Algert Global LLC acquired a new position in Certara during the second quarter valued at approximately $156,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.